83 FR 13632 - New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship; Change of a Sponsor's Name and Address
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 83, Issue 62 (March 30, 2018)
Food and Drug Administration
Federal Register Volume 83, Issue 62 (March 30, 2018)
| Page Range | 13632-13637 | |
| FR Document | 2018-06358 |
[Federal Register Volume 83, Number 62 (Friday, March 30, 2018)] [Rules and Regulations] [Pages 13632-13637] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-06358] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Parts 510, 520, 522, 524, 556, and 558 [Docket No. FDA-2017-N-0002] New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship; Change of a Sponsor's Name and Address AGENCY: Food and Drug Administration, HHS. ACTION: Final rule; technical amendments. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during July, August, and September 2017. FDA is informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to reflect the withdrawal of approval of applications, changes of sponsorship of applications, and a change of a sponsor's name and address, and to make technical amendments to improve the accuracy of the regulations. DATES: This rule is effective March 30, 2018, except for amendatory instructions 3 to 21 CFR 510.600, 9 to 21 CFR 522.300, 10 to 21 CFR 522.540, and 11 to 21 CFR 522.1081, which are effective April 9, 2018. FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-402-5689, [email protected]. SUPPLEMENTARY INFORMATION: I. Approval Actions FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during July, August, and September 2017, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the internet may obtain these documents at the CVM FOIA Electronic Reading Room: https://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm. Marketing exclusivity and patent information may be accessed in FDA's publication, Approved Animal Drug Products Online (Green Book) at: https://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/default.htm. Table 1--Original and Supplemental NADAs and ANADAs Approved During July, August, and September 2017 -------------------------------------------------------------------------------------------------------------------------------------------------------- Approval date File No. Sponsor Product name Species Effect of the action Public documents -------------------------------------------------------------------------------------------------------------------------------------------------------- July 21, 2017........... 141-450 Intervet, Inc., 2 BANAMINE Transdermal Cattle.............. Original approval for FOI Summary; EA/ Giralda Farms, (flunixin transdermal the control of pyrexia FONSI.\1\ Madison, NJ 07940. solution) Solution. associated with bovine respiratory disease and the control of pain associated with foot rot in steers, beef heifers, beef cows, beef bulls intended for slaughter, and replacement dairy heifers under 20 months of age. [[Page 13633]] July 19, 2017........... 141-336 ECO LLC, 344 Nassau AIVLOSIN (tylvalosin Swine............... Supplemental approval FOI Summary. St., Princeton, NJ tartrate) Water Soluble for control of swine 08540. Granules. respiratory disease (SRD) associated with Bordetella bronchiseptica, Haemophilus parasuis, Pasteurella multocida, and Streptococcus suis in groups of swine in buildings experiencing an outbreak of SRD. July 14, 2017........... 200-620 Aurora ALTREN (altrenogest) Horses.............. Original approval as a FOI Summary. Pharmaceutical, Solution. generic copy of NADA LLC, 1196 Highway 131-310. 3 South, Northfield, MN 55057-3009. July 14, 2017........... 200-621 Aurora SWINEMATE (altrenogest) Swine............... Original approval as a FOI Summary. Pharmaceutical, Solution. generic copy of NADA LLC, 1196 Highway 141-222. 3 South, Northfield, MN 55057-3009. September 15, 2017...... 141-250 Zoetis Inc., 333 Chlortetracycline and Cattle.............. Supplemental approval ..................... Portage St., lasalocid Type B and of revised Kalamazoo, MI Type C medicated feeds. representative 49007. labeling making technical amendments. September 28, 2017...... 141-333 Virbac AH, Inc., SENTINEL SPECTRUM Dogs................ Supplemental approval FOI Summary. 3200 Meacham (milbemycin oxime/ for the treatment and Blvd., Ft. Worth, lufenuron/praziquantel). control of the adult TX 76137. tapeworm Dipylidium caninum. -------------------------------------------------------------------------------------------------------------------------------------------------------- \1\ The Agency has carefully considered an environmental assessment (EA) of the potential environmental impact of this action and has made a finding of no significant impact (FONSI). II. Change of Sponsorship SmartVet USA, Inc., 22201 West Innovation Dr., suite 170A, Olathe, KS 66061-1304 has informed FDA that it has transferred ownership of, and all rights and interest in, the following application to Sparhawk Laboratories, Inc., 12340 Santa Fe Trail Dr., Lenexa, KS 66215: ------------------------------------------------------------------------ File No. Product name 21 CFR Section ------------------------------------------------------------------------ 200-348........................ ECOMECTIN (ivermectin) 524.1193 Topical Solution. ------------------------------------------------------------------------ Following this withdrawal of approval, SmartVet USA, Inc. is no longer the sponsor of an approved application. Accordingly, it will be removed from the list of sponsors of approved applications in Sec. 510.600(c) (21 CFR 510.600(c)). Strategic Veterinary Pharmaceuticals, Inc., 100 NW. Airport Rd., St. Joseph, MO 64503 has informed FDA that it has transferred ownership of, and all rights and interest in, the following application to Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland: ------------------------------------------------------------------------ File No. Product name 21 CFR Section ------------------------------------------------------------------------ 109-305........................ Oxytocin Injection.... 522.1680 ------------------------------------------------------------------------ The animal drug regulations are being amended to reflect these changes of sponsorship. III. Withdrawals of Approval The following sponsors requested that FDA withdraw approval of the NADAs listed in the following table because the products are no longer manufactured or marketed: ---------------------------------------------------------------------------------------------------------------- File No. Sponsor Product name 21 CFR Section ---------------------------------------------------------------------------------------------------------------- 047-055............................. Watson Laboratories, Inc., Chorionic Gonadotropin 522.1081 311 Bonnie Circle, Corona, Powder for Injection. CA 92880. 104-606............................. Watson Laboratories, Inc., Dexamethasone Sodium 522.540 311 Bonnie Circle, Corona, Phosphate Injection. CA 92880. [[Page 13634]] 139-633............................. Wildlife Laboratories, Inc., WILDNIL (carfentanil 522.300 1230 W. Ash St., Suite D, citrate) Injection. Windsor, CO 80550. ---------------------------------------------------------------------------------------------------------------- Following this withdrawal of approval, Watson Laboratories, Inc. is no longer the sponsor of an approved application. Accordingly, it will be removed from the list of sponsors of approved applications in Sec. 510.600(c). Elsewhere in this issue of the Federal Register, FDA gave notice that approval of NADAs 047-055, 104-606, and 139-633, and all supplements and amendments thereto, is withdrawn, effective April 9, 2018. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect these actions. IV. Technical Amendments Western Chemical, Inc., 1269 Lattimore Rd., Ferndale, WA 98248 has informed FDA that it has changed its name and address to Syndel USA, 1441 W. Smith Rd., Ferndale, WA 98248. ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305-3115 has informed FDA that it has changed its name to ADM Animal Nutrition, Inc. Accordingly, we are amending Sec. 510.600(c) to reflect these changes. We are also making technical amendments to update the scientific name of a pathogenic bacterium, to accurately list the concentrations of ingredients in a combination new animal drug, and to correctly list the assay limits and maximum drug concentration in Type B medicated feeds for a combination new animal drug used in feed. These actions are being taken to improve the accuracy of the regulations. V. Legal Authority This final rule is issued under section 512(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C.360b(i)), which requires Federal Register publication of ``notice[s] . . . effective as a regulation,'' of the conditions of use of approved new animal drugs. This rule sets forth technical amendments to the regulations to codify recent actions on approved new animal drug applications and corrections to improve the accuracy of the regulations, and as such does not impose any burden on regulated entities. Although denominated a rule pursuant to the FD&C Act, this document does not meet the definition of ``rule'' in 5 U.S.C. 804(3)(A) because it is a ``rule of particular applicability.'' Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808. Likewise, this is not a rule subject to Executive Order 12866, which defines a rule as ``an agency statement of general applicability and future effect, which the agency intends to have the force and effect of law, that is designed to implement, interpret, or prescribe law or policy or to describe the procedure or practice requirements of an agency.'' List of Subjects 21 CFR Part 510 Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements. 21 CFR Parts 520, 522, and 524 Animal drugs. 21 CFR Part 556 Animal drugs, Food. 21 CFR Part 558 Animal drugs, Animal feeds. Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 510, 520, 522, 524, 556, and 558 are amended as follows: PART 510--NEW ANIMAL DRUGS 0 1. The authority citation for part 510 continues to read as follows: Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e. 0 2. In Sec. 510.600, in the table in paragraph (c)(1), remove the entries for ``ADM Alliance Nutrition, Inc.'', ``SmartVet USA, Inc.'' and ``Western Chemical, Inc.'', and add entries for ``ADM Animal Nutrition, Inc.'' and ``Syndel USA'' in alphabetical order; and in the table in paragraph (c)(2), remove the entry for ``086001'' and revise the entries for ``012286'' and ``050378'' to read as follows: Sec. 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications. * * * * * (c) * * * (1) * * * ------------------------------------------------------------------------ Drug labeler Firm name and address code ------------------------------------------------------------------------ * * * * * * * ADM Animal Nutrition, Inc., 1000 North 30th St., Quincy, 012286 IL 62305-3115.......................................... * * * * * * * Syndel USA, 1441 W. Smith Rd., Ferndale, WA 98248....... 050378 * * * * * * * ------------------------------------------------------------------------ (2) * * * -------------------------------------------------------------------------------------------------------------------------------------------------------- Drug labeler code Firm name and address -------------------------------------------------------------------------------------------------------------------------------------------------------- * * * * * * * 012286..................................... ADM Animal Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305-3115. [[Page 13635]] * * * * * * * 050378..................................... Syndel USA, 1441 W. Smith Rd., Ferndale, WA 98248. * * * * * * * -------------------------------------------------------------------------------------------------------------------------------------------------------- 0 3. Effective April 9, 2018,'' in Sec. 510.600, in the table in paragraph (c)(1), remove the entry for ``Watson Laboratories, Inc.''; and in the table in paragraph (c)(2), remove the entry for ``000402''. PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS 0 4. The authority citation for part 520 continues to read as follows: Authority: 21 U.S.C. 360b. Sec. 520.48 [Amended] 0 5. In Sec. 520.48, in paragraph (b), remove ``000061 and 061623'' and in its place add ``000061, 051072, and 061623''. Sec. 520.1447 [Amended] 0 6. In Sec. 520.1447, in paragraph (d)(1)(ii), remove ``(Taenia pisiformis, Echinococcus multilocularis, and E. granulosus)'' and in its place add ``(Dipylidium caninum, Taenia pisiformis, Echinococcus multilocularis, and E. granulosus)''. 0 7. In Sec. 520.2645, revise paragraphs (d)(1) and (2) to read as follows: Sec. 520.2645 Tylvalosin. * * * * * (d) * * * (1) Amount. Administer 50 parts per million (ppm) tylvalosin continuously in drinking water for 5 consecutive days. (2) Indications for use. For control of porcine proliferative enteropathy (PPE) associated with Lawsonia intracellularis infection in groups of swine in buildings experiencing an outbreak of PPE; and for control of swine respiratory disease (SRD) associated with Bordetella bronchiseptica, Haemophilus parasuis, Pasteurella multocida, and Streptococcus suis in groups of swine in buildings experiencing an outbreak of SRD. * * * * * PART 522--IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS 0 8. The authority citation for part 522 continues to read as follows: Authority: 21 U.S.C. 360b. Sec. 522.300 [Removed] 0 9. Effective April 9, 2018, remove Sec. 522.300. 0 10. Effective April 9, 2018, in Sec. 522.540, revise paragraphs (b)(2) and (c)(2) to read as follows: Sec. 522.540 Dexamethasone solution. * * * * * (b) * * * (2) Sponsor. See No. 061623 in Sec. 510.600(c) of this chapter. * * * * * (c) * * * (2) Sponsor. See No. 061623 in Sec. 510.600(c) of this chapter. * * * * * Sec. 522.1081 [Amended] 0 11. Effective April 9, 2018, in Sec. 522.1081, in paragraph (b)(1), remove ``Nos. 000402 and 054771'' and in its place add ``No. 054771''. Sec. 522.1662a [Amended] 0 12. In Sec. 522.1662a, in paragraph (h)(3)(ii), remove ``Spherophorus necrophorus'' and in its place add ``Fusobacterium necrophorum''. Sec. 522.1680 [Amended] 0 13. In Sec. 522.1680, in paragraph (b), remove ``054628,''. PART 524--OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS 0 14. The authority citation for part 524 continues to read as follows: Authority: 21 U.S.C. 360b. 0 15. Add Sec. 524.970 to read as follows: Sec. 524.970 Flunixin. (a) Specifications. Each milliliter of solution contains 50 milligrams (mg) flunixin (equivalent to 83 mg flunixin meglumine). (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter. (c) Related tolerances. See Sec. 556.286 of this chapter. (d) Conditions of use--(1) Amount. Apply only once at a dose of 3.3 mg flunixin per kg body weight (1.5 mg/lb; 3 mL per 100 lbs) topically in a narrow strip along the dorsal midline from the withers to the tailhead. (2) Indications for use. For the control of pyrexia associated with bovine respiratory disease and the control of pain associated with foot rot in steers, beef heifers, beef cows, beef bulls intended for slaughter, and replacement dairy heifers under 20 months of age. (3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Cattle must not be slaughtered for human consumption within 8 days of the last treatment. Not for use in female dairy cattle 20 months of age or older, including dry dairy cows; use in these cattle may cause drug residues in milk and/or in calves born to these cows or heifers. Not for use in suckling beef calves, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves. 0 16. In Sec. 524.1132, revise paragraph (a) to read as follows: Sec. 524.1132 Hydrocortisone, miconazole, and gentamicin otic suspension. (a) Specifications. Each milliliter (mL) of suspension contains 1.11 milligrams (mg) hydrocortisone aceponate, 17.4 mg miconazole nitrate, and 1.5 mg gentamicin (as gentamicin sulfate). * * * * * Sec. 524.1193 [Amended] 0 17. In Sec. 524.1193, in paragraph (b)(2), remove ``086001'' and in its place add ``058005''. PART 556--TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD 0 18. The authority citation for part 556 continues to read as follows: Authority: 21 U.S.C. 342, 360b, 371. Sec. 556.286 [Amended] 0 19. In Sec. 556.286, in paragraph (c), remove ``Sec. Sec. 522.956 and 522.970'' and in its place add ``Sec. Sec. 522.956, 522.970, and 524.970''. PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS 0 20. The authority citation for part 558 continues to read as follows: Authority: 21 U.S.C. 354, 360b, 360ccc, 360ccc-1, 371. 0 21. In Sec. 558.4, in paragraph (d), in the ``Category II'' table, revise the row entries for ``Neomycin'' through ``Pyrantel tartrate'' to read as follows: [[Page 13636]] Sec. 558.4 Requirement of a medicated feed mill license. * * * * * (d) * * * Category II ---------------------------------------------------------------------------------------------------------------- Assay limits Assay limits Drug percent \1\ Type B maximum (100x) percent \1\ Type Type A \1\ B/C \2\ ---------------------------------------------------------------------------------------------------------------- * * * * * * * Neomycin.................................... 80-120 20 g/lb (4.4%)................. 70-125 Oxytetracycline............................. 80-120 20 g/lb (4.4%)................. 65-135 Neomycin sulfate............................ 80-120 100 g/lb (22.0%)............... 70-125 Nicarbazin (granular)....................... 90-110 5.675 g/lb (1.25%)............. 85-115/75-125 Narasin..................................... 90-110 5.675 g/lb (1.25%)............. 85-115/75-125 Nicarbazin (powder)......................... 98-106 5.675 g/lb (1.25%)............. 85-115/80-120 Novobiocin.................................. 85-115 17.5 g/lb (3.85%).............. 80-120 Pyrantel tartrate........................... 90-110 36 g/lb (7.9%)................. 75-125 * * * * * * * ---------------------------------------------------------------------------------------------------------------- \1\ Percent of labeled amount. \2\ Values given represent ranges for either Type B or Type C medicated feeds. For those drugs that have two range limits, the first set is for a Type B medicated feed and the second set is for a Type C medicated feed. These values (ranges) have been assigned in order to provide for the possibility of dilution of a Type B medicated feed with lower assay limits to make a Type C medicated feed. * * * * * 0 22. In Sec. 558.128, revise paragraphs (e)(3)(vi), (e)(4)(ix), and (e)(4)(xxvi) to read as follows: Sec. 558.128 Chlortetracycline. * * * * * (e) * * * (3) * * * ---------------------------------------------------------------------------------------------------------------- Combination in Chlortetracycline amount grams/ton Indications for use Limitations Sponsor ---------------------------------------------------------------------------------------------------------------- * * * * * * * (vi) 10 mg/lb of body weight... Tiamulin hydrogen For control of swine Feed chlortetracycline 058198 fumarate, 35. dysentery associated at approximately 400 069254 with Brachyspira g/ton of feed, (formerly Serpulina varying with body or Treponema) weight and food hyodysenteriae consumption, to susceptible to provide 10 mg/lb of tiamulin and for body weight. Feed treatment of swine continuously as the bacterial enteritis sole ration for 14 caused by E. coli and days. Withdraw Salmonella medicated feed 2 days choleraesuis before slaughter. sensitive to Tiamulin as provided chlortetracycline and by Nos. 058198 or treatment of 069254 in Sec. bacterial pneumonia 510.600(c) of this caused by P. chapter. multocida sensitive to chlortetracycline. ---------------------------------------------------------------------------------------------------------------- (4) * * * ---------------------------------------------------------------------------------------------------------------- Combination in Chlortetracycline amount grams/ton Indications for use Limitations Sponsor ---------------------------------------------------------------------------------------------------------------- [[Page 13637]] * * * * * * * (ix) 500 to 4,000 to provide 10 Lasalocid, 30 to Pasture cattle Feed continuously on a 054771 mg/lb of body weight daily. 600. (slaughter, stocker, hand-fed basis for feeder cattle, dairy not more than 5 days and beef replacement to provide 10 mg heifers): For chlortetracycline per treatment of lb. body weight per bacterial enteritis day and not less than caused by E. coli and 60 mg or more than bacterial pneumonia 300 mg lasalocid per caused by P. head per day in at multocida organisms least 1 pound of susceptible to feed. Daily lasalocid chlortetracycline; intakes in excess of and for increased 200 mg/head/day in rate of weight gain. pasture cattle have not been shown to be more effective than 200 mg lasalocid/head/ day. Do not allow horses or other equines access to feeds containing lasalocid. No withdrawal period is required. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. See Sec. 558.311(d) of this chapter. Lasalocid as provided by No. 054771 in Sec. 510.600(c) of this chapter. * * * * * * * (xxvi) 500 to 4,000 to provide Lasalocid, 30 to Cattle weighing up to Hand feed continuously 054771 10 mg/head/day. 181.8. 800 pounds: For the for not more than 5 treatment of days at a rate of 10 bacterial enteritis mg chlortetracycline caused by E. coli and and 1 mg lasalocid bacterial pneumonia per 2.2 lb. body caused by P. weight daily to multocida susceptible cattle with a maximum to chlortetracycline; of 360 mg of and for the control lasalocid per head of coccidiosis caused per day. Do not allow by Eimeria bovis and horses or other E. zuernii. equines access to feeds containing lasalocid. No withdrawal period is required. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. See Sec. 558.311(d) of this chapter. Lasalocid as provided by No. 054771 in Sec. 510.600(c) of this chapter. ---------------------------------------------------------------------------------------------------------------- * * * * * 0 23. In Sec. 558.325, revise paragraph (d)(2) to read as follows: Sec. 558.325 Lincomycin. * * * * * (d) * * * (2) The expiration date of VFDs for lincomycin medicated feeds must not exceed 6 months from the date of issuance. VFDs for lincomycin shall not be refilled. * * * * * Sec. 558.575 [Amended] 0 24. In Sec. 558.575, in paragraph (e)(2)(ii) remove ``and bacterial infections due to H. galmaxima,''. Dated: March 21, 2018. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2018-06358 Filed 3-29-18; 8:45 am] BILLING CODE 4164-01-P
![13632 Federal Register / Vol. 83, No. 62 / Friday, March 30, 2018 / Rules and Regulations
§ 134.1112 The decision. Dated: March 14, 2018. DATES: This rule is effective March 30,
(a) Timing. The Judge shall decide a Linda E. McMahon, 2018, except for amendatory
CVE Appeal, insofar as practicable, Administrator. instructions 3 to 21 CFR 510.600, 9 to
within 60 calendar days after close of [FR Doc. 2018–06034 Filed 3–29–18; 8:45 am] 21 CFR 522.300, 10 to 21 CFR 522.540,
the record. BILLING CODE 8025–01–P
and 11 to 21 CFR 522.1081, which are
(b) Contents. Following closure of the effective April 9, 2018.
record, the Judge will issue a decision FOR FURTHER INFORMATION CONTACT:
containing findings of fact and George K. Haibel, Center for Veterinary
conclusions of law, reasons for such DEPARTMENT OF HEALTH AND Medicine (HFV–6), Food and Drug
findings and conclusions, and any relief HUMAN SERVICES Administration, 7500 Standish Pl.,
ordered. Rockville, MD 20855, 240–402–5689,
(c) Basis for decision. Decisions under Food and Drug Administration george.haibel@fda.hhs.gov.
this subpart will be based primarily on
the evidence in the CVE case file, SUPPLEMENTARY INFORMATION:
21 CFR Parts 510, 520, 522, 524, 556,
arguments made on appeal, and any and 558 I. Approval Actions
response(s) thereto. However, the Judge,
in his/her sole discretion, may consider FDA is amending the animal drug
[Docket No. FDA–2017–N–0002] regulations to reflect approval actions
issues beyond those raised in the
pleadings and the denial or cancellation for NADAs and ANADAs during July,
New Animal Drugs; Approval of New
letter. August, and September 2017, as listed
Animal Drug Applications; Withdrawal
(d) Finality. The decision is the final in table 1. In addition, FDA is informing
of Approval of New Animal Drug
agency decision and becomes effective the public of the availability, where
Applications; Changes of
upon issuance. Where OHA dismisses applicable, of documentation of
Sponsorship; Change of a Sponsor’s
an appeal of a D/CVE denial or environmental review required under
Name and Address
cancellation, the D/CVE determination the National Environmental Policy Act
remains in effect. AGENCY: Food and Drug Administration, (NEPA) and, for actions requiring
(e) Service. OHA will serve a copy of HHS. review of safety or effectiveness data,
all written decisions on each party, or, Final rule; technical
ACTION: summaries of the basis of approval (FOI
if represented by counsel, on its amendments. Summaries) under the Freedom of
counsel. Information Act (FOIA). These public
(f) Effect. If the Judge grants the SUMMARY: The Food and Drug documents may be seen in the Dockets
appeal and finds the appellant eligible Administration (FDA or we) is Management Staff (HFA–305), Food and
for inclusion in the CVE database, the amending the animal drug regulations to Drug Administration, 5630 Fishers
D/CVE must immediately reinstate or reflect application-related actions for Lane, Rm. 1061, Rockville, MD 20852,
include the appellant, as the case may new animal drug applications (NADAs) between 9 a.m. and 4 p.m., Monday
be, in the CVE database. and abbreviated new animal drug through Friday. Persons with access to
(g) Reconsideration. A decision of the applications (ANADAs) during July, the internet may obtain these
Judge may be reconsidered. Any party August, and September 2017. FDA is documents at the CVM FOIA Electronic
that has appeared in the proceeding, or informing the public of the availability Reading Room: https://www.fda.gov/
the Secretary of VA or his or her of summaries of the basis of approval AboutFDA/CentersOffices/
designee, may request reconsideration and of environmental review OfficeofFoods/CVM/
by filing with OHA and serving a documents, where applicable. The CVMFOIAElectronicReadingRoom/
petition for reconsideration on all animal drug regulations are also being default.htm. Marketing exclusivity and
parties to the CVE Appeal within twenty amended to reflect the withdrawal of patent information may be accessed in
(20) calendar days after service of the approval of applications, changes of FDA’s publication, Approved Animal
written decision, upon a clear showing sponsorship of applications, and a Drug Products Online (Green Book) at:
of an error of fact or law material to the change of a sponsor’s name and address, https://www.fda.gov/AnimalVeterinary/
decision. The Judge also may reconsider and to make technical amendments to Products/ApprovedAnimal
a decision on his or her own initiative. improve the accuracy of the regulations. DrugProducts/default.htm.
TABLE 1—ORIGINAL AND SUPPLEMENTAL NADAS AND ANADAS APPROVED DURING JULY, AUGUST, AND SEPTEMBER
2017
Public
Approval date File No. Sponsor Product name Species Effect of the action documents
July 21, 2017 .... 141–450 Intervet, Inc., 2 BANAMINE Cattle ........... Original approval for the control of FOI Summary;
Giralda Farms, Transdermal pyrexia associated with bovine res- EA/FONSI.1
Madison, NJ (flunixin piratory disease and the control of
07940. transdermal pain associated with foot rot in
solution) Solu- steers, beef heifers, beef cows, beef
tion. bulls intended for slaughter, and re-
placement dairy heifers under 20
months of age.
amozie on DSK30RV082PROD with RULES
VerDate Sep<11>2014 18:02 Mar 29, 2018 Jkt 244001 PO 00000 Frm 00008 Fmt 4700 Sfmt 4700 E:\FR\FM\30MRR1.SGM 30MRR1](https://thefederalregister.org/doc/83_FR_13694/page/1.svg)
![13634 Federal Register / Vol. 83, No. 62 / Friday, March 30, 2018 / Rules and Regulations
21 CFR
File No. Sponsor Product name Section
139–633 ......................... Wildlife Laboratories, Inc., 1230 W. Ash St., WILDNIL (carfentanil citrate) Injection ................. 522.300
Suite D, Windsor, CO 80550.
Following this withdrawal of V. Legal Authority 21 CFR Parts 520, 522, and 524
approval, Watson Laboratories, Inc. is This final rule is issued under section
no longer the sponsor of an approved Animal drugs.
512(i) of the Federal Food, Drug, and
application. Accordingly, it will be Cosmetic Act (FD&C Act) (21 21 CFR Part 556
removed from the list of sponsors of U.S.C.360b(i)), which requires Federal
approved applications in § 510.600(c). Animal drugs, Food.
Register publication of ‘‘notice[s] . . .
Elsewhere in this issue of the Federal effective as a regulation,’’ of the 21 CFR Part 558
Register, FDA gave notice that approval conditions of use of approved new
of NADAs 047–055, 104–606, and 139– Animal drugs, Animal feeds.
animal drugs. This rule sets forth
633, and all supplements and technical amendments to the regulations Therefore, under the Federal Food,
amendments thereto, is withdrawn, to codify recent actions on approved Drug, and Cosmetic Act and under
effective April 9, 2018. As provided in new animal drug applications and authority delegated to the Commissioner
the regulatory text of this document, the corrections to improve the accuracy of of Food and Drugs, 21 CFR parts 510,
animal drug regulations are amended to the regulations, and as such does not 520, 522, 524, 556, and 558 are
reflect these actions. impose any burden on regulated amended as follows:
IV. Technical Amendments entities.
Although denominated a rule PART 510—NEW ANIMAL DRUGS
Western Chemical, Inc., 1269 pursuant to the FD&C Act, this
Lattimore Rd., Ferndale, WA 98248 has document does not meet the definition ■ 1. The authority citation for part 510
informed FDA that it has changed its of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because continues to read as follows:
name and address to Syndel USA, 1441 it is a ‘‘rule of particular applicability.’’ Authority: 21 U.S.C. 321, 331, 351, 352,
W. Smith Rd., Ferndale, WA 98248. Therefore, it is not subject to the 353, 360b, 371, 379e.
ADM Alliance Nutrition, Inc., 1000 congressional review requirements in 5 ■ 2. In § 510.600, in the table in
North 30th St., Quincy, IL 62305–3115 U.S.C. 801–808. Likewise, this is not a paragraph (c)(1), remove the entries for
has informed FDA that it has changed rule subject to Executive Order 12866, ‘‘ADM Alliance Nutrition, Inc.’’,
its name to ADM Animal Nutrition, Inc. which defines a rule as ‘‘an agency ‘‘SmartVet USA, Inc.’’ and ‘‘Western
Accordingly, we are amending statement of general applicability and Chemical, Inc.’’, and add entries for
§ 510.600(c) to reflect these changes. future effect, which the agency intends ‘‘ADM Animal Nutrition, Inc.’’ and
We are also making technical to have the force and effect of law, that ‘‘Syndel USA’’ in alphabetical order;
amendments to update the scientific is designed to implement, interpret, or and in the table in paragraph (c)(2),
name of a pathogenic bacterium, to prescribe law or policy or to describe remove the entry for ‘‘086001’’ and
accurately list the concentrations of the procedure or practice requirements revise the entries for ‘‘012286’’ and
ingredients in a combination new of an agency.’’ ‘‘050378’’ to read as follows:
animal drug, and to correctly list the List of Subjects
assay limits and maximum drug § 510.600 Names, addresses, and drug
concentration in Type B medicated 21 CFR Part 510 labeler codes of sponsors of approved
applications.
feeds for a combination new animal Administrative practice and
drug used in feed. These actions are procedure, Animal drugs, Labeling, * * * * *
being taken to improve the accuracy of Reporting and recordkeeping (c) * * *
the regulations. requirements. (1) * * *
Drug labeler
Firm name and address code
* * * * * * *
ADM Animal Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115 ......................................................................................... 012286
* * * * * * *
Syndel USA, 1441 W. Smith Rd., Ferndale, WA 98248 ..................................................................................................................... 050378
* * * * * * *
(2) * * *
amozie on DSK30RV082PROD with RULES
Drug labeler code Firm name and address
* * * * * * *
012286 ........................................................................................... ADM Animal Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.
VerDate Sep<11>2014 18:02 Mar 29, 2018 Jkt 244001 PO 00000 Frm 00010 Fmt 4700 Sfmt 4700 E:\FR\FM\30MRR1.SGM 30MRR1](https://thefederalregister.org/doc/83_FR_13694/page/3.svg)
![Federal Register / Vol. 83, No. 62 / Friday, March 30, 2018 / Rules and Regulations 13635
Drug labeler code Firm name and address
* * * * * * *
050378 ........................................................................................... Syndel USA, 1441 W. Smith Rd., Ferndale, WA 98248.
* * * * * * *
■ 3. Effective April 9, 2018,’’ in § 522.300 [Removed] respiratory disease and the control of
§ 510.600, in the table in paragraph ■ 9. Effective April 9, 2018, remove pain associated with foot rot in steers,
(c)(1), remove the entry for ‘‘Watson § 522.300. beef heifers, beef cows, beef bulls
Laboratories, Inc.’’; and in the table in intended for slaughter, and replacement
■ 10. Effective April 9, 2018, in
paragraph (c)(2), remove the entry for dairy heifers under 20 months of age.
§ 522.540, revise paragraphs (b)(2) and
‘‘000402’’. (3) Limitations. Federal law restricts
(c)(2) to read as follows:
this drug to use by or on the order of
PART 520—ORAL DOSAGE FORM § 522.540 Dexamethasone solution. a licensed veterinarian. Cattle must not
NEW ANIMAL DRUGS be slaughtered for human consumption
* * * * *
(b) * * * within 8 days of the last treatment. Not
■ 4. The authority citation for part 520 for use in female dairy cattle 20 months
(2) Sponsor. See No. 061623 in
continues to read as follows: of age or older, including dry dairy
§ 510.600(c) of this chapter.
Authority: 21 U.S.C. 360b. cows; use in these cattle may cause drug
* * * * *
residues in milk and/or in calves born
§ 520.48 [Amended] (c) * * *
to these cows or heifers. Not for use in
(2) Sponsor. See No. 061623 in
■ 5. In § 520.48, in paragraph (b), suckling beef calves, dairy calves, and
§ 510.600(c) of this chapter.
remove ‘‘000061 and 061623’’ and in its veal calves. A withdrawal period has
* * * * * not been established for this product in
place add ‘‘000061, 051072, and
061623’’. § 522.1081 [Amended] pre-ruminating calves.
■ 16. In § 524.1132, revise paragraph (a)
§ 520.1447 [Amended] ■ 11. Effective April 9, 2018, in
to read as follows:
§ 522.1081, in paragraph (b)(1), remove
■ 6. In § 520.1447, in paragraph ‘‘Nos. 000402 and 054771’’ and in its § 524.1132 Hydrocortisone, miconazole,
(d)(1)(ii), remove ‘‘(Taenia pisiformis, place add ‘‘No. 054771’’. and gentamicin otic suspension.
Echinococcus multilocularis, and E. (a) Specifications. Each milliliter (mL)
granulosus)’’ and in its place add § 522.1662a [Amended]
of suspension contains 1.11 milligrams
‘‘(Dipylidium caninum, Taenia ■ 12. In § 522.1662a, in paragraph (mg) hydrocortisone aceponate, 17.4 mg
pisiformis, Echinococcus multilocularis, (h)(3)(ii), remove ‘‘Spherophorus miconazole nitrate, and 1.5 mg
and E. granulosus)’’. necrophorus’’ and in its place add gentamicin (as gentamicin sulfate).
■ 7. In § 520.2645, revise paragraphs ‘‘Fusobacterium necrophorum’’. * * * * *
(d)(1) and (2) to read as follows: § 522.1680 [Amended] § 524.1193 [Amended]
§ 520.2645 Tylvalosin. ■ 13. In § 522.1680, in paragraph (b), ■ 17. In § 524.1193, in paragraph (b)(2),
* * * * * remove ‘‘054628,’’. remove ‘‘086001’’ and in its place add
(d) * * * ‘‘058005’’.
PART 524—OPHTHALMIC AND
(1) Amount. Administer 50 parts per
TOPICAL DOSAGE FORM NEW PART 556—TOLERANCES FOR
million (ppm) tylvalosin continuously
ANIMAL DRUGS RESIDUES OF NEW ANIMAL DRUGS
in drinking water for 5 consecutive
days. IN FOOD
■ 14. The authority citation for part 524
(2) Indications for use. For control of continues to read as follows: ■ 18. The authority citation for part 556
porcine proliferative enteropathy (PPE) Authority: 21 U.S.C. 360b. continues to read as follows:
associated with Lawsonia intracellularis
infection in groups of swine in ■ 15. Add § 524.970 to read as follows: Authority: 21 U.S.C. 342, 360b, 371.
buildings experiencing an outbreak of § 524.970 Flunixin. § 556.286 [Amended]
PPE; and for control of swine respiratory (a) Specifications. Each milliliter of ■ 19. In § 556.286, in paragraph (c),
disease (SRD) associated with Bordetella solution contains 50 milligrams (mg) remove ‘‘§§ 522.956 and 522.970’’ and
bronchiseptica, Haemophilus parasuis, flunixin (equivalent to 83 mg flunixin in its place add ‘‘§§ 522.956, 522.970,
Pasteurella multocida, and meglumine). and 524.970’’.
Streptococcus suis in groups of swine in (b) Sponsor. See No. 000061 in
buildings experiencing an outbreak of § 510.600(c) of this chapter. PART 558—NEW ANIMAL DRUGS FOR
SRD. (c) Related tolerances. See § 556.286 USE IN ANIMAL FEEDS
* * * * * of this chapter.
(d) Conditions of use—(1) Amount. ■ 20. The authority citation for part 558
PART 522—IMPLANTATION OR Apply only once at a dose of 3.3 mg continues to read as follows:
amozie on DSK30RV082PROD with RULES
INJECTABLE DOSAGE FORM NEW flunixin per kg body weight (1.5 mg/lb; Authority: 21 U.S.C. 354, 360b, 360ccc,
ANIMAL DRUGS 3 mL per 100 lbs) topically in a narrow 360ccc–1, 371.
strip along the dorsal midline from the ■ 21. In § 558.4, in paragraph (d), in the
■ 8. The authority citation for part 522 withers to the tailhead. ‘‘Category II’’ table, revise the row
continues to read as follows: (2) Indications for use. For the control entries for ‘‘Neomycin’’ through
Authority: 21 U.S.C. 360b. of pyrexia associated with bovine ‘‘Pyrantel tartrate’’ to read as follows:
VerDate Sep<11>2014 18:02 Mar 29, 2018 Jkt 244001 PO 00000 Frm 00011 Fmt 4700 Sfmt 4700 E:\FR\FM\30MRR1.SGM 30MRR1](https://thefederalregister.org/doc/83_FR_13694/page/4.svg)
![Federal Register / Vol. 83, No. 62 / Friday, March 30, 2018 / Rules and Regulations 13637
Chlortetracycline Combination in Indications for use Limitations Sponsor
amount grams/ton
* * * * * * *
(ix) 500 to 4,000 to Lasalocid, 30 to 600 Pasture cattle (slaughter, stocker, feeder Feed continuously on a hand-fed basis 054771
provide 10 mg/lb of cattle, dairy and beef replacement for not more than 5 days to provide
body weight daily. heifers): For treatment of bacterial en- 10 mg chlortetracycline per lb. body
teritis caused by E. coli and bacterial weight per day and not less than 60
pneumonia caused by P. multocida mg or more than 300 mg lasalocid per
organisms susceptible to chlortetra- head per day in at least 1 pound of
cycline; and for increased rate of feed. Daily lasalocid intakes in excess
weight gain. of 200 mg/head/day in pasture cattle
have not been shown to be more ef-
fective than 200 mg lasalocid/head/
day. Do not allow horses or other
equines access to feeds containing
lasalocid. No withdrawal period is re-
quired. A withdrawal period has not
been established for this product in
pre-ruminating calves. Do not use in
calves to be processed for veal. See
§ 558.311(d) of this chapter. Lasalocid
as provided by No. 054771 in
§ 510.600(c) of this chapter.
* * * * * * *
(xxvi) 500 to 4,000 to Lasalocid, 30 to Cattle weighing up to 800 pounds: For Hand feed continuously for not more 054771
provide 10 mg/ 181.8. the treatment of bacterial enteritis than 5 days at a rate of 10 mg chlor-
head/day. caused by E. coli and bacterial pneu- tetracycline and 1 mg lasalocid per
monia caused by P. multocida sus- 2.2 lb. body weight daily to cattle with
ceptible to chlortetracycline; and for a maximum of 360 mg of lasalocid per
the control of coccidiosis caused by head per day. Do not allow horses or
Eimeria bovis and E. zuernii. other equines access to feeds con-
taining lasalocid. No withdrawal period
is required. A withdrawal period has
not been established for this product
in pre-ruminating calves. Do not use
in calves to be processed for veal.
See § 558.311(d) of this chapter.
Lasalocid as provided by No. 054771
in § 510.600(c) of this chapter.
* * * * * Dated: March 21, 2018. SUMMARY: The Food and Drug
Leslie Kux, Administration (FDA) is withdrawing
■ 23. In § 558.325, revise paragraph
Associate Commissioner for Policy. approval of three new animal drug
(d)(2) to read as follows: applications (NADAs). This action is
[FR Doc. 2018–06358 Filed 3–29–18; 8:45 am]
§ 558.325 Lincomycin. BILLING CODE 4164–01–P being taken at the sponsors’ request
because these products are no longer
* * * * *
manufactured or marketed.
(d) * * * DEPARTMENT OF HEALTH AND DATES: Withdrawal of approval is
(2) The expiration date of VFDs for HUMAN SERVICES effective April 9, 2018.
lincomycin medicated feeds must not
Food and Drug Administration FOR FURTHER INFORMATION CONTACT:
exceed 6 months from the date of
Sujaya Dessai, Center for Veterinary
issuance. VFDs for lincomycin shall not
21 CFR Part 522 Medicine (HFV–212), Food and Drug
be refilled. Administration, 7519 Standish Pl.,
* * * * * [Docket No. FDA–2017–N–0002]
Rockville, MD 20855, 240–402–5761,
New Animal Drugs; Withdrawal of sujaya.dessai@fda.hhs.gov.
§ 558.575 [Amended]
Approval of New Animal Drug SUPPLEMENTARY INFORMATION: During
■ 24. In § 558.575, in paragraph (e)(2)(ii) Applications July and August 2017, the following
remove ‘‘and bacterial infections due to sponsors requested that FDA withdraw
AGENCY: Food and Drug Administration,
H. galmaxima,’’. HHS. approval of the NADAs listed in the
following table because the products are
ACTION: Notification of withdrawal.
no longer manufactured or marketed:
amozie on DSK30RV082PROD with RULES
21 CFR
File No. Sponsor Product name section
047–055 ......................... Watson Laboratories, Inc., 311 Bonnie Circle, Chorionic Gonadotropin Powder for Injection ...... 522.1081
Corona, CA 92880.
VerDate Sep<11>2014 18:02 Mar 29, 2018 Jkt 244001 PO 00000 Frm 00013 Fmt 4700 Sfmt 4700 E:\FR\FM\30MRR1.SGM 30MRR1](https://thefederalregister.org/doc/83_FR_13694/page/6.svg)
Document Created: 2018-11-01 08:58:52
Document Modified: 2018-11-01 08:58:52
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Rules and Regulations | |
| Action | Final rule; technical amendments. | |
| Dates | This rule is effective March 30, 2018, except for amendatory instructions 3 to 21 CFR 510.600, 9 to 21 CFR 522.300, 10 to 21 CFR 522.540, and 11 to 21 CFR 522.1081, which are effective April 9, 2018. | |
| Contact | George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-402-5689, [email protected] | |
| FR Citation | 83 FR 13632 | |
| CFR Citation | 21
CFR
510 21 CFR 520 21 CFR 522 21 CFR 524 21 CFR 556 21 CFR 558 | |
| CFR Associated | Administrative Practice and Procedure; Animal Drugs; Labeling; Reporting and Recordkeeping Requirements; Food and Animal Feeds |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR